During infection with Mycoplasma pneumoniae the site of' localization of the organism appears to be superf'icial, involving only the epithelial layer of the respiratory passages (8) . Studies in hamsters performed by Fernald and Clyde (11) suggest that local respiratory tract immune mechanisms play a greater role in resistance to the organism than do systemic immune mechanisms. Taken together, these findings suggest that evidence of specit'ic M. pneumoniae immunity should be demonstrable in the respiratory tract or its secretions. Previous attempts to demonstrate local antibody to M. pneumoniae in the respiratory tract of experimentally infected volunteers failed, probably due to the relative insensitivity of' the methods employed (2, 10, 20) . However, Biberfeld and Sterner (3) reported the presence of immunoglobulin(Ig) A, IgG, and IgM antibodies in bronchial secretions of patients with lower respiratory illness due to M. pneumoniae, by use of immunofluorescence and complement fixation techniques.
This report describes the development of' M. pneumoniae antibody in nasal secretions and sputa of a significant proportion of volunteers 'Present address: Institute for Medical Microbiology, 63 Giessen, Schubertstr. 1, Germany.
after intranasal inoculation of the organism. These antibodies were found to be predominantly of the IgA class. Furthermore, the presence of such antibody prior to challenge appeared to be correlated with resistance to illness. The possible implications of these findings to the problem of immunoprophylaxis of M. pneumoniae inf'ections are discussed.
MATERIALS AND METHODS Volunteers were healthy adult male inmates of the federal prison system or the Texas Department of Correction. The two studies included in this report were conducted to evaluate two ditf'erent preparations of' killed M. pneumoniae vaccine in man. The f'irst study was performed in 1965-1966 and has been described in detail previously (20) . The inactivated vaccine used in this study was prepared from a culture of' the FH strain of' M. pneumoniae grown in a medium consisting ot' a chemically defined solution of amino acids and vitamins enriched with a chloroform extract of egg yolk. The organisms were inactivated with Formalin and then concentrated by centritugation. Twenty-two men, 16 vaccinees and 6 controls, were examined for local antibody prior to and at various time intervals after challenge with wild-type 4 weeks after the injection of inactivated vaccine. In this study two vaccinees developed febrile respiratory disease and 6 developed afebrile respiratory disease. In the control group of unvaccinated volunteers, six developed febrile respiratory disease whereas three had an afebrile illness. In the second study the vaccine was prepared by growing M. pneumoniae on the glass surface of 5-liter Povitsky bottles (23) . The medium contained bovine serum fraction instead of horse serum. The cell sheet adhering to the glass surface was washed several times and scraped into distilled water. The organisms were then inactivated with Formalin.
Organisms and cultural conditions. M. pneumoniae strain PI 1428 in its second passage on artificial medium was used as the challenge inoculum. The same organism suspension was used in both studies. The growth medium has been described in detail previously (6) . M. pneumoniae was grown on the glass surface of 5-liter Povitsky bottles containing 500 ml of medium, and the organisms were harvested after incubation at 37 C for 11 days by scraping the cell sheet into the broth medium. The suspension was distributed in glass ampoules and stored at -70 C until used. Volunteers were inoculated into the nasopharynx with 106 to 107 colony-forming units of this strain.
Collection and processing of specimens. Nasal secretions and sputa from the first study were collected and concentrated by lyophilization as described elsewhere (16) . The nasal washings in study 2 were concentrated using Sephadex G200. The concentrated specimens were adjusted to approximately 10 to 20 mg of IgA per 100 ml (as determined with serum IgA standard).
Ig determinations. IgA, IgG, and IgM in nasal secretions and sputa were determined by use of the radial immunodiffusion method of Mancini et al. (17) . Serum standards were used as reference. The diffusion plates and standards were obtained from Meloy Laboratories, Springfield, Va. The mean level of IgA was 32.5 mg/100 ml for sputa from study 1, 21.2 mg/100 ml for nasal washings from study 1 and 15.2 mg/100 for nasal washings from study 2. IgG levels were 19.6 mg/100 ml for sputa from study 1, 26.4 mg/100 ml for nasal washings from study 1, and 0.9 mg/100 ml for nasal washings from study 2. The reason for the low levels of IgG in the second study is not understood. Levels of IgM were low in each instance: 1.2 mg/100 ml for sputa from study 1, 4.5 mg/100 ml for nasal washings from study 1, and < 1 mg/100 ml for nasal washings from study 2 Med., in press). Briefly, '4C-oleic acid-and "4C-palmitic acid-labeled M. pneumoniae organisms were filtered (450-nm pore size membrane filter, Millipore
Corp.) and diluted to an activity of 500 to 1,000 dpm per 0.025 ml. Fourfold dilutions of nasal secretions or sputa were prepared in microtiter plates, and these diluted materials were incubated with 0.025 ml of labeled antigen for 60 min at 37 C and overnight at 4 C. Antigen-antibody complexes were precipitated by a 1:4 dilution of antiserum to human IgA, IgG, IgM, or a 1:8 dilution of antiserum for whole human serum. After centrifugation of the precipitates at 1,000 rpm for 10 min, the radioactivity remaining in the supernatant fluid was determined. The antibody titer was defined as the highest specimen dilution giving a 33% binding of antigen. Each specimen was tested in duplicate. Titers of secretions were calculated on the basis of 20 mg/100 ml of IgA.
MCT. The mycoplasmacidal test was based on the complement-mediated mycoplasma killing reaction originally described by Gale and Kenny (14) . Details of the method were published earlier (5) . For the study of large numbers of specimens which were available in small volume, the test was adapted to microtiter equipment. To 3 fourfold dilutions of the test specimen which were prepared in 0.05 ml of' tris(hydrochloride)aminomethane -ethylenediaminetetraacetic acid-saline (TES)-buffered saline containing divalent cations and 0.1% gelatin, 0.1 ml of a filtered (450-nm pore size membrane filter, Millipore Corp.) suspension of M. pneumoniae organisms was added. After incubation for 60 min at 4 C, 0.05 ml of prediluted guinea pig serum which served as the source of complement was added and the plates were incubated for 120 min at 37 C. After vigorous shaking 0.1 ml of the reaction mixture was removed and diluted 1 25 . Test specimen alone (in the highest concentration used), fresh guinea pig serum alone, and diluent alone were included in each assay as controls. Based on the average number of viable organisms in the controls, the extent of killing by test serum in the presence of complement was determined. The highest dilution of the best specimen which produced a 0% decrease in viability was calculated after logit transformation.
CF and MI. Complement fixation (CF) and metabolism inhibition (MI) procedures for measurement of serum antibodies were performed as described previously (25, 26) .
RESULTS
Adequacy of anti-globulin antisera employed in RIP reaction. As shown in Table 1 the surface of M. pneumoniae organisms, although this is unlikely since the organisms were grown on glass and were washed extensively. Nevertheless, the secretory antibodies which developed after challenge could have been directed against horse serum or yeast extract protein rather than M. pneumoniae. For this reason we incubated five postchallenge sputa and three postchallenge nasal secretions with an equal volume of a 1:10 or 1:20 dilution of complete mycoplasma broth for 1 h at 37 C, and then for 18 h at 4 C, thus providing an excess of horse and yeast proteins for absorption of antibodies against these antigens. As a control, the nasal secretions or sputa were preincubated with buff'er for 1 h at 37 C, and then for 18 h at 4 C. After the 18-h incubation interval the nasal secretions or sputa, now diluted 1: 2, were tested by the standard RIP procedure. In no instance did prior absorption (Fig. 4) . (P < .01; Wilcoxon-Mann-Whitney-test) (15) . The volunteers from this study were divided into two As shown in Fig. 1 , the geometric mean titer of IgA antibody to M. pneumoniae in sputum increased during the first 3 weeks after infection and apparently decreased thereafter. IgG antibody was detected in some sputa, but an increase in geometric mean titer was not observed. The values in the figure represent geometric means obtained on the 22 volunteers of the first study. Figures 2 and 3 represent the data obtained on the nasal washings from study 1. As shown in Fig. 2 , IgA antibody to M. pneumoniae in nasal secretions increased during the first week, remained at this level for the following 2 weeks, and showed a tendency to decrease thereafter. When an antiserum to whole human serum was employed to precipitate antigen-antibody complexes, the geometric approximately equal groups of men, one with low serum MI antibody (1:8 or less) and the other with high serum antibody (> 1: 8). These groups were then subdivided into subgroups of men with low (<1:3) or high (>1:3) nasal secretion antibody. Men with low levels of RIP nasal antibody ( < 1: 3) developed M. pneumoniae disease with higher frequency than men with a high antibody titer ( > 1: 3), irrespective of serum titer (Table 5 ). The correlation of nasal antibody with resistance was significant for the group of men with a serum antibody titer of 1:8 or more (P = 0.04; Fisher exact test). In contrast, a correlation of serum antibody with resistance was not evident (P > 0.30). These findings suggest that local IgA antibody, as measured by the RIP test, was related to resistance to M. pneumoniae disease.
Correlation of rise in local antibody with disease. There was also a correlation observed between the occurrence of illness and the development of a local secretory antibody response as shown in Table 6 . Men with M. pneumoniae disease developed a rise in local antibody significantly more frequently than men who failed to become ill.
Correlation of nasal secretion RIP antibody and serum CF and MI antibodies. Volunteers who possessed nasal secretion RIP antibody also tended to have serum CF and MI antibodies ( Fig. 5 and 6 ). Individuals with high levels of RIP antibody generally had high levels of serum antibodies.
DISCUSSION
Although reinfection with M. pneumoniae occurs with appreciable frequency under epidemic conditions, the decrease in incidence of M. pneumoniae disease which occurs with increase in age after the third decade suggests that infection stimulates host defense mechanisms which are relatively effective in protecting against this type of illness (13, 24) . In the experimentally infected hamster, M. pneumoniae localizes on the surface of the ciliated respiratory epithelium of the bronchi (8 that the most effective protection would be provided by immunological defense mechanisms which operate at the epithelial surface of the respiratory tract. For this reason, it was not surprising to detect IgA antibody for M. pneumoniae in respiratory tract secretions. Previously Biberfeld and Sterner (3) had described the presence of antibody in sputum after natural infection with M. pneumoniae. These antibodies were detected in IgA, IgG, and IgM globulins in comparable amounts, and for this reason the possibility that the sputum specimens were contaminated with serum could not be excluded. In the present study significant increases in antibody activity in nasal secretion and sputum were predominantly in the IgA class of globulins. These results are in good agreement with the nature of the local respiratory tract antibody response to viruses (9, 19, 21, 27) .
Failure to detect M. pneumoniae antibody in respiratory tract secretions in previous studies can be attributed in part to the relative insensitivity of the methods used when compared to the RIP procedure (2, 10, 20) . In addition, the test methods previously used included the metabolism-inhibition antibody assay which measures complement-dependent antibody.
In the present study an increase in local IgA antibody was detected after experimental infection of a majority of the volunteers studied. Furthermore, analysis of the response to experimental M. pneumoniae challenge of volunteers with different levels of preexisting respiratory tract IgA antibody suggested that this secretory antibody was related to host resistance to M. pneumoniae disease.
Fernald et al. (12) We have suggested previously that the organism damages lung tissue by the production and release of H202 (7, 22) . This type of epithelial cell damage is made possible by the ability of the organism to adsorb to the surface of respiratory epithelium and thus H202 can be delivered directly to the target area without inactivation from extracellular catalase and peroxidase. In this situation antibody might have an effect by preventing adsorption of organisms onto the respiratory epithelium. This type of effect has recently been described for certain oral bacteria which attach to the buccal epithelial surface (28) . It is also possible that IgA antibody might be opsonic and aid in phagocytosis of M. pneumoniae. This possibility is rather unlikely, since IgA does not appear to be efficient in opsonization (4) .
Our findings in this study have several implications to current efforts for the prevention of M. pneumoniae disease by immunoprophylaxis. First, the existence of a local secretory IgA M. pneumoniae antibody system in the respiratory tract offers additional hope for the success of a live vaccine. Presumably, attenuated live organisms introduced into the upper respiratory passages should be able to stimulate a local IgA antibody response. Second, the correlation of local antibody with resistance to M. pneumoniae disease suggests that this type of antibody should be measured when experimental vaccines, live or inactivated, are being evaluated for evidence of antigenicity. It is likely that the RIP measurement of local antibody will provide a helpful new parameter to vaccine evaluation.
